Eintrag weiter verarbeiten
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysi...
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Journal of Clinical Oncology, 30, 2012, 15_suppl, S. 10501-10501 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael |
|---|---|
| author |
Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael |
| spellingShingle |
Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael Journal of Clinical Oncology Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. Cancer Research Oncology |
| author_sort |
singer, christian f. |
| spelling |
Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10501 <jats:p> 10501 </jats:p><jats:p> Background: Estrogen receptor alpha (ERα) expression is a prognostic parameter in breast cancer and predicts response to endocrine therapy. One of the factors important for protein expression is amplification of its encoding gene ESR1. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer. Methods: 394 patients who had been randomized into the tamoxifen-only arm of the prospectively designed endocrine ABCSG-06 trial and in whom FFPE tumor tissue was available were included in this analysis. Immunohistochemical ERα expression was evaluated both locally and centrally using the Allred score, while ESR1 gene amplification status was evaluated by FISH analysis using the ESR1/CEN6 ratio. Results: ESR1 copy number gains were detected in 187 of 394 (47%) tumor specimen and was associated with favorable clinical outcome. At a median follow-up of 10 years, women with intratumoral ESR1 copy number gains had a significantly longer distant recurrence-free survival (adjusted HR for relapse 0.48; 95% CI 0.28-0.83; p=0.009) and breast cancer-specific survival (adjusted HR for death 0.46; CI 0.46-0.71; p=0.006) when compared to women with normal ESR1 copy numbers. Immunohistochemical ERα protein expression, evaluated by Allred score, was significantly correlated with ESR1 copy number alterations (p<0.0001; Chi-Square test), but did itself not allow to discriminate between patients with poor and good prognosis. Conclusions: ESR1 amplification status is an independent and powerful predictor for long-term distant recurrence-free and breast cancer-specific survival in postmenopausal women with endocrine-responsive early-stage breast cancer who received 5 years of tamoxifen. </jats:p> Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2012.30.15_suppl.10501 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4xMDUwMQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4xMDUwMQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2012 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
singer2012estrogenreceptoralphaesr1geneamplificationstatusandclinicaloutcomeintamoxifentreatedpostmenopausalpatientswithendocrineresponsiveearlybreastcancerananalysisoftheprospectiveabcsg6trial |
| publishDateSort |
2012 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_unstemmed |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_full |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_fullStr |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_full_unstemmed |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_short |
Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_sort |
estrogen receptor alpha (<i>esr1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: an analysis of the prospective abcsg-6 trial. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10501 |
| publishDate |
2012 |
| physical |
10501-10501 |
| description |
<jats:p> 10501 </jats:p><jats:p> Background: Estrogen receptor alpha (ERα) expression is a prognostic parameter in breast cancer and predicts response to endocrine therapy. One of the factors important for protein expression is amplification of its encoding gene ESR1. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer. Methods: 394 patients who had been randomized into the tamoxifen-only arm of the prospectively designed endocrine ABCSG-06 trial and in whom FFPE tumor tissue was available were included in this analysis. Immunohistochemical ERα expression was evaluated both locally and centrally using the Allred score, while ESR1 gene amplification status was evaluated by FISH analysis using the ESR1/CEN6 ratio. Results: ESR1 copy number gains were detected in 187 of 394 (47%) tumor specimen and was associated with favorable clinical outcome. At a median follow-up of 10 years, women with intratumoral ESR1 copy number gains had a significantly longer distant recurrence-free survival (adjusted HR for relapse 0.48; 95% CI 0.28-0.83; p=0.009) and breast cancer-specific survival (adjusted HR for death 0.46; CI 0.46-0.71; p=0.006) when compared to women with normal ESR1 copy numbers. Immunohistochemical ERα protein expression, evaluated by Allred score, was significantly correlated with ESR1 copy number alterations (p<0.0001; Chi-Square test), but did itself not allow to discriminate between patients with poor and good prognosis. Conclusions: ESR1 amplification status is an independent and powerful predictor for long-term distant recurrence-free and breast cancer-specific survival in postmenopausal women with endocrine-responsive early-stage breast cancer who received 5 years of tamoxifen. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
10501 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792323159577329666 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:29:22.418Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Estrogen+receptor+alpha+%28ESR1%29+gene+amplification+status+and+clinical+outcome+in+tamoxifen-treated+postmenopausal+patients+with+endocrine-responsive+early+breast+cancer%3A+An+analysis+of+the+prospective+ABCSG-6+trial.&rft.date=2012-05-20&genre=article&issn=1527-7755&volume=30&issue=15_suppl&spage=10501&epage=10501&pages=10501-10501&jtitle=Journal+of+Clinical+Oncology&atitle=Estrogen+receptor+alpha+%28%3Ci%3EESR1%3C%2Fi%3E%29+gene+amplification+status+and+clinical+outcome+in+tamoxifen-treated+postmenopausal+patients+with+endocrine-responsive+early+breast+cancer%3A+An+analysis+of+the+prospective+ABCSG-6+trial.&aulast=Gnant&aufirst=Michael&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.15_suppl.10501&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792323159577329666 |
| author | Singer, Christian F., Holst, Frederik, Steurer, Stefan, Burandt, E C, Samonigg, Hellmut, Jakesz, Raimund, Stoeger, Herbert, Greil, Richard, Sauter, Guido, Filipits, Martin, Simon, Ronald, Gnant, Michael |
| author_facet | Singer, Christian F., Holst, Frederik, Steurer, Stefan, Burandt, E C, Samonigg, Hellmut, Jakesz, Raimund, Stoeger, Herbert, Greil, Richard, Sauter, Guido, Filipits, Martin, Simon, Ronald, Gnant, Michael, Singer, Christian F., Holst, Frederik, Steurer, Stefan, Burandt, E C, Samonigg, Hellmut, Jakesz, Raimund, Stoeger, Herbert, Greil, Richard, Sauter, Guido, Filipits, Martin, Simon, Ronald, Gnant, Michael |
| author_sort | singer, christian f. |
| container_issue | 15_suppl |
| container_start_page | 10501 |
| container_title | Journal of Clinical Oncology |
| container_volume | 30 |
| description | <jats:p> 10501 </jats:p><jats:p> Background: Estrogen receptor alpha (ERα) expression is a prognostic parameter in breast cancer and predicts response to endocrine therapy. One of the factors important for protein expression is amplification of its encoding gene ESR1. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer. Methods: 394 patients who had been randomized into the tamoxifen-only arm of the prospectively designed endocrine ABCSG-06 trial and in whom FFPE tumor tissue was available were included in this analysis. Immunohistochemical ERα expression was evaluated both locally and centrally using the Allred score, while ESR1 gene amplification status was evaluated by FISH analysis using the ESR1/CEN6 ratio. Results: ESR1 copy number gains were detected in 187 of 394 (47%) tumor specimen and was associated with favorable clinical outcome. At a median follow-up of 10 years, women with intratumoral ESR1 copy number gains had a significantly longer distant recurrence-free survival (adjusted HR for relapse 0.48; 95% CI 0.28-0.83; p=0.009) and breast cancer-specific survival (adjusted HR for death 0.46; CI 0.46-0.71; p=0.006) when compared to women with normal ESR1 copy numbers. Immunohistochemical ERα protein expression, evaluated by Allred score, was significantly correlated with ESR1 copy number alterations (p<0.0001; Chi-Square test), but did itself not allow to discriminate between patients with poor and good prognosis. Conclusions: ESR1 amplification status is an independent and powerful predictor for long-term distant recurrence-free and breast cancer-specific survival in postmenopausal women with endocrine-responsive early-stage breast cancer who received 5 years of tamoxifen. </jats:p> |
| doi_str_mv | 10.1200/jco.2012.30.15_suppl.10501 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC4xNV9zdXBwbC4xMDUwMQ |
| imprint | American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2012 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T11:29:22.418Z |
| match_str | singer2012estrogenreceptoralphaesr1geneamplificationstatusandclinicaloutcomeintamoxifentreatedpostmenopausalpatientswithendocrineresponsiveearlybreastcancerananalysisoftheprospectiveabcsg6trial |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 10501-10501 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Singer, Christian F. Holst, Frederik Steurer, Stefan Burandt, E C Samonigg, Hellmut Jakesz, Raimund Stoeger, Herbert Greil, Richard Sauter, Guido Filipits, Martin Simon, Ronald Gnant, Michael 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10501 <jats:p> 10501 </jats:p><jats:p> Background: Estrogen receptor alpha (ERα) expression is a prognostic parameter in breast cancer and predicts response to endocrine therapy. One of the factors important for protein expression is amplification of its encoding gene ESR1. We have investigated the value of ESR1 amplification in predicting the long-term clinical outcome in tamoxifen-treated postmenopausal women with endocrine-responsive breast cancer. Methods: 394 patients who had been randomized into the tamoxifen-only arm of the prospectively designed endocrine ABCSG-06 trial and in whom FFPE tumor tissue was available were included in this analysis. Immunohistochemical ERα expression was evaluated both locally and centrally using the Allred score, while ESR1 gene amplification status was evaluated by FISH analysis using the ESR1/CEN6 ratio. Results: ESR1 copy number gains were detected in 187 of 394 (47%) tumor specimen and was associated with favorable clinical outcome. At a median follow-up of 10 years, women with intratumoral ESR1 copy number gains had a significantly longer distant recurrence-free survival (adjusted HR for relapse 0.48; 95% CI 0.28-0.83; p=0.009) and breast cancer-specific survival (adjusted HR for death 0.46; CI 0.46-0.71; p=0.006) when compared to women with normal ESR1 copy numbers. Immunohistochemical ERα protein expression, evaluated by Allred score, was significantly correlated with ESR1 copy number alterations (p<0.0001; Chi-Square test), but did itself not allow to discriminate between patients with poor and good prognosis. Conclusions: ESR1 amplification status is an independent and powerful predictor for long-term distant recurrence-free and breast cancer-specific survival in postmenopausal women with endocrine-responsive early-stage breast cancer who received 5 years of tamoxifen. </jats:p> Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. Journal of Clinical Oncology |
| spellingShingle | Singer, Christian F., Holst, Frederik, Steurer, Stefan, Burandt, E C, Samonigg, Hellmut, Jakesz, Raimund, Stoeger, Herbert, Greil, Richard, Sauter, Guido, Filipits, Martin, Simon, Ronald, Gnant, Michael, Journal of Clinical Oncology, Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial., Cancer Research, Oncology |
| title | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_full | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_fullStr | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_full_unstemmed | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_short | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| title_sort | estrogen receptor alpha (<i>esr1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: an analysis of the prospective abcsg-6 trial. |
| title_unstemmed | Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10501 |